HIV Postexposure Prophylaxis Guidelines

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

ATLANTA-Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].

ATLANTA—Health care personnel exposed to HIV should be evaluated within hours (rather than days) after their exposure and should be tested for HIV at baseline (ie, to establish infection status at the time of exposure), according to the latest HIV postexposure prophylaxis (PEP) guidelines from the US Public Health Service [MMWR 50:(RR11):1-42, 2001].

Because most occupational HIV exposures do not result in the transmission of HIV, potential toxicity must be carefully considered when prescribing PEP (see Table). Health care personnel with occupational exposure to HIV should receive follow-up counseling, postexposure testing, and medical evaluation, regardless of whether they receive PEP. For management resources, see PEPline (www.ucsf.edu/hivcntr) and Needlestick! (www.needlestick.mednet.ucla.edu).

The basic 2-drug PEP regimens, given for 4 weeks, as recommended in the Table, are zidovudine (Retrovir)/lamivudine (Epivir) (available as Combivir); lamivudine/stavudine (Zerit); and didanosine (Videx)/stavudine.

The expanded 3-drug regimen consists of a basic regimen plus indinavir (Crixivan), nelfinavir (Viracept), efavirenz (Sustiva), or abacavir (Ziagen). Abacavir is available in combination with zidovudine and lamivudine as Trizivir.

Drugs for use as PEP with expert consultation include ritonavir (Norvir), saquinavir (Fortovase), amprenavir (Agenerase), delavirdine (Rescriptor), and lopinavir/ritonavir (Kaletra). 

Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
4 experts in this video
4 experts in this video
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
7 experts are featured in this series.
Related Content